Loading...

Alexa Fluor® 700 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_Alx700_020608
C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 700
  • 30-F11_Alx700_020608
    C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 700
  • 54_Mouse_Liver_Ecadherin_CD45
    Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: E-Cadherin (red) in Cycle 1 and CD45 (cyan) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
103127 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103128 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Stoupa A, et al. 2018. EMBO Mol Med. 10:. PubMed
  2. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  3. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  4. Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed
  5. Wong Fok Lung T, et al. 2020. Nat Microbiol. 141:5. PubMed
  6. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  7. Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed
  8. Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed
  9. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
  10. Guzzi N et al. 2018. Cell. 173(5):1204-1216 . PubMed
  11. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  12. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  13. Daskou M, et al. 2022. PLoS Pathog. 18:e1010160. PubMed
  14. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  15. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  16. Xi H, et al. 2016. J Exp Med. 213: 189 - 207. PubMed
  17. Hu X, et al. 2016. Nat Commun. 7:13095. PubMed
  18. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  19. Gimblet C et al. 2017. Cell host & microbe. 22(1):13-24 . PubMed
  20. Putnam NE, et al. 2019. PLoS Pathog. 15:e1007744. PubMed
  21. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  22. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  23. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  24. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  25. Katsura A, et al. 2017. Mol Oncol. 11:1241. PubMed
  26. Amir M, et al. 2018. Cell Rep. 25:3733. PubMed
  27. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  28. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  29. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  30. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  31. Fujii Y, et al. 2022. JBMR Plus. 6:e10562. PubMed
  32. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  33. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  34. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  35. Wang X, et al. 2020. Signal Transduct Target Ther. 5:35. PubMed
  36. Egusquiza RJ, et al. 2020. Environ Health Perspect. 128:47011. PubMed
  37. McDowell SAC, et al. 2021. Nat Cancer. 2:545. PubMed
  38. Reyes RM, et al. 2021. Oncoimmunology. 10:2006529. PubMed
  39. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  40. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  41. Yang R, et al. 2012. J Immunol. 189:2656. PubMed
  42. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  43. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  44. van Elsas MJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  45. Stutchfield B, et al. 2015. Gastroenterology. 149: 1896-1909.e14. PubMed
  46. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  47. Sun L, et al. 2020. J Immunol. 2177:204. PubMed
  48. Magupalli VG, et al. 2020. Science. :369. PubMed
  49. Li J, et al. 2020. Cancer Discov. . PubMed
  50. Daubeuf F, et al. 2017. Curr Protoc Mouse Biol. 10.1002/cpmo.26. PubMed
  51. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  52. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  53. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  54. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
  55. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  56. Tanaka S, et al. 2012. J Immunol. 188:6145. PubMed
  57. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  58. Fantauzzi MF, et al. 2021. ERJ Open Res. 7: . PubMed
  59. Daubeuf F, et al. 2021. Cells. 10:. PubMed
  60. An J, et al. 2022. iScience. 25:103570. PubMed
  61. Chen ELY, et al. 2021. Cell Rep. 35:109227. PubMed
  62. Menzel L, et al. 2022. STAR Protoc. 3:101267. PubMed
  63. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  64. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  65. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  66. Levi J, et al. 2020. J Nucl Med. . PubMed
  67. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  68. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  69. Duque-Correa MA, et al. 2022. Nat Commun. 13:1725. PubMed
  70. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  71. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  72. Tomlinson KL, et al. 2021. Nat Commun. 12:1399. PubMed
  73. Benne N, et al. 2020. Adv Healthc Mater. 9:e2000043. PubMed
  74. Prados A, et al. 2021. Nat Immunol. 22:510. PubMed
  75. Coursey T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.83. PubMed
  76. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  77. Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed
  78. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  79. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  80. Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed
  81. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  82. Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed
  83. Li J, et al. 2018. Immunity. 49:178. PubMed
  84. Garcia LR, et al. 2021. Nat Commun. 12:3364. PubMed
  85. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  86. Zhao F, et al. 2022. Nat Commun. 13:6117. PubMed
  87. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  88. Abboud D, et al. 2015. Sci Rep. 5: 14746. PubMed
  89. O'Connor T, et al. 2020. Cancer Cell. 36(3):250-267. PubMed
  90. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  91. Acker KP, et al. 2019. iScience. 19:281. PubMed
  92. Schmid MC, et al. 2022. Nat Commun. 13:1768. PubMed
  93. Chen X, et al. 2022. Front Immunol. 13:828319. PubMed
  94. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  95. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  96. Frank E, et al. 2016. Toxicol Pathol. 10.1177/0192623315620587. PubMed
  97. Hiebert P et al. 2018. Developmental cell. 46(2):145-161 . PubMed
  98. Sitaraman S, et al. 2019. Sci Rep. 9:12509. PubMed
  99. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  100. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  101. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  102. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  103. Leyva‐Castillo JM et al. 2019. Immunity. 50(5):1262-1275 . PubMed
  104. Avraham S, et al. 2019. Oncogene. 38:3812. PubMed
  105. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  106. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  107. Zhang HG, et al. 2022. Cell Res. :. PubMed
  108. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  109. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  110. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  111. Clark JT, et al. 2021. eLife. 10:00. PubMed
  112. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  113. Ahn D, et al. 2021. Cell Reports. 35(9):109196. PubMed
  114. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  115. Philip E Boulais et al. 2018. Immunity. 49(4):627-639 . PubMed
  116. Crauste F, et al. 2017. Cell Syst. 0.379166667. PubMed
  117. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  118. Ma J, et al. 2021. J Transl Med. 19:477. PubMed
  119. Artham S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L750:318. PubMed
  120. Vacca F, et al. 2020. eLife. 9:e54017.. PubMed
  121. Ji G, et al. 2019. Bone Joint J. 101-B:108. PubMed
  122. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  123. Stevenson ER, et al. 2022. J Pharmacol Exp Ther. 382:356. PubMed
  124. Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed
  125. Dustin CM, et al. 2021. J Immunol. 206:2989. PubMed
  126. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  127. Bollenbach M, et al. 2021. Molecules. 26:. PubMed
  128. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  129. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  130. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  131. Zhang MS, et al. 2022. Nat Commun. 13:954. PubMed
  132. Liu W, et al. 2022. J Clin Invest. 132: . PubMed
  133. Gicheva N, et al. 2016. Biochem Biophys Res Commun. 479:1-4. PubMed
  134. Natale CA, et al. 2018. Elife. 7. PubMed
  135. Ayturk UM, et al. 2020. J Bone Miner Res. 35:1981. PubMed
  136. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  137. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  138. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  139. Cambridge E, et al. 2017. Exp Hematol. 45:64-68.e5. PubMed
  140. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  141. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  142. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  143. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  144. Korin B, et al. 2020. Sleep. :43. PubMed
  145. Van der Meer JM, et al. 2020. Cancer Immunol Immunother. . PubMed
  146. Molgora M, et al. 2020. Cell. 182:886. PubMed
  147. Aguilar-Pimentel A, et al. 2017. PLoS One. 12(6):e0178563. PubMed
  148. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  149. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  150. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  151. Zhang Z, et al. 2020. Front Immunol. 11:583276. PubMed
  152. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  153. Melhem NJ, et al. 2021. Circulation. 143:566. PubMed
  154. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  155. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  156. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  157. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
  158. Guey B, et al. 2014. Proc Natl Acad Sci U S A. 111:17254. PubMed
  159. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  160. Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed
  161. Litwinoff EMS, et al. 2017. Obes Res Clin Pract. 12:174. PubMed
  162. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  163. Dye BR, et al. 2020. Biomaterials. 234:119757. PubMed
  164. Lee GR, et al. 2021. JCI Insight. 6:. PubMed
  165. Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed
  166. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  167. Tian F, et al. 2016. Nat Commun. 7:13283. PubMed
  168. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
  169. Peltzer N, et al. 2018. Nature. 557:112. PubMed
  170. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  171. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
  172. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  173. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  174. Pattabiraman G, et al. 2021. Am J Physiol Renal Physiol. . PubMed
  175. Chen Y, et al. 2022. Stem Cells Int. 2022:1309684. PubMed
  176. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  177. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  178. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  179. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  180. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  181. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  182. Rossi G, et al. 2022. Sci Rep. 12:13380. PubMed
  183. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
RRID
AB_493714 (BioLegend Cat. No. 103127)
AB_493715 (BioLegend Cat. No. 103128)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 4    Revision Date: 04.20.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account